Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Change in Cash (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Change in Cash data on record, last reported at -$854000.0 in Q3 2025.

  • For Q3 2025, Change in Cash rose 40.69% year-over-year to -$854000.0; the TTM value through Sep 2025 reached -$2.7 million, up 82.19%, while the annual FY2024 figure was -$19.3 million, 1.65% up from the prior year.
  • Change in Cash reached -$854000.0 in Q3 2025 per MBRX's latest filing, down from -$159000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $71.1 million in Q1 2021 and bottomed at -$8.1 million in Q2 2022.
  • Average Change in Cash over 5 years is -$445789.5, with a median of -$5.1 million recorded in 2023.
  • Peak YoY movement for Change in Cash: surged 7681.18% in 2021, then crashed 398.25% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$4.3 million in 2021, then tumbled by 69.52% to -$7.2 million in 2022, then skyrocketed by 85.8% to -$1.0 million in 2023, then tumbled by 398.25% to -$5.1 million in 2024, then skyrocketed by 83.34% to -$854000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$854000.0 in Q3 2025, -$159000.0 in Q2 2025, and $3.4 million in Q1 2025.